Table 2 Clinical baseline characteristics of GBM patient samples (n = 46)
From: System-based approaches as prognostic tools for glioblastoma
| Newly-diagnosed (n = 31, 67%) | Recurrent (n = 15, 33%) | |
|---|---|---|
| Age (median, range) [years] | 57 (16–75) | 53 (12–74) |
| Sex | ||
| M | 14 (45%) | 10 (67%) |
| F | 17 (55%) | 5 (33%) |
| Location | ||
| Left side | 10 (32%) | 3 (20%) |
| Right side | 18 (58%) | 10 (67%) |
| Other | 2 (6%) | 2 (13%) |
| Not available | 1 (3%) | |
| MGMT promoter methylation | ||
| Methylated | 11 (35%) | 6 (40%) |
| Unmethylated | 14 (45%) | 8 (53%) |
| Not available | 6 (19%) | 1 (7%) |
| Treatment | ||
| None | 31 (100%) | 6 (40%) |
| TMZ + radiotherapy | 7 (47%) | |
| TMZ + radiotherapy + Avastin + Irinotecan | 1 (7%) | |
| TMZ + radiotherapy + Cilengitide | 1 (7%) | |
| PFS (median, 95%CI) [months] | 11.1 (8.4–16.8) | 5.8 (2.3–7.6) |
